Published in:
Open Access
01-04-2014 | Poster presentation
Histidine-rich glycoprotein prevents septic lethality through neutrophil regulation
Authors:
M Nishibori, H Wake, S Mori, K Liu, Y Morioka, K Teshigawara, M Sakaguchi, K Kuroda, H Takahashi, A Ohtsuka, T Yoshino, H Morimatsu
Published in:
Critical Care
|
Special Issue 2/2014
Login to get access
Excerpt
Although there have been many clinical trials for treatment of sepsis, no drugs are available at present. Sepsis is thought to be complex disorders; activation/lesion of vascular endothelial cells, accelerated coagulation and platelet aggregation, leukocyte activation or paralysis, and hypercytokinemia. To treat the pathological status of sepsis, it must be necessary to control these plural disorders simultaneously or sequentially. In the present study, we identified and characterized a plasma protein histidine-rich glycoprotein (HRG) as a factor that decreases dramatically in septic condition and maintains neutrophil's shape and functional quiescence. We clarified the involvement of HRG in septic pathogenesis and propose a novel therapy for sepsis based on that. …
